Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Ixazomib

Ixazomib Capsules

Trial Locations (10)

100020

Beijing Chaoyang Hospital Capital Medical University, Beijing

100191

Peking University Third Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

110004

Shengjing Hospital of China Medical University, Shenyang

200001

Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai

200003

Shanghai Chang Zheng Hospital, Shanghai

200025

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai

210029

Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing

310003

1st Affiliated Hospital of Zhejiang University, Hangzhou

430030

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT03748953 - Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | Biotech Hunter | Biotech Hunter